Skip to main content
Clinical Trials/CTRI/2011/06/001820
CTRI/2011/06/001820
Completed
Phase 3

Clinical Study to assess the efficacy and safety of fixed dose combination of S-Amlodipine besilate, Olmesartan medoxomil and Hydrochlorothiazide tablets in hypertension - SAOH

Emcure Pharmaceuticals Ltd Pune0 sites200 target enrollmentTBD

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
Not specified
Sponsor
Emcure Pharmaceuticals Ltd Pune
Enrollment
200
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Sponsor
Emcure Pharmaceuticals Ltd Pune

Eligibility Criteria

Inclusion Criteria

  • Male or female patients between 18\-65 years of age, Subjects diagnosed with essential hypertension not controlled on monotherapy or two drug therapy or newly diagnosed Stage II hypertensives, Subject willing to give written informed consent and willing to comply with study protocol

Exclusion Criteria

  • Subjects previously sensitive to any of the ingredients of the fixed dose combination under study or calcium channel blockers or angiotensin receptor blockers or thiazide diuretic, Subjects with history of secondary or malignant hypertension, Patients with known significant respiratory/liver/kidney/neurological diseases / uncontrolled diabetes, Patients with evidence of any cardiac arrhythmia on ECG, Pregnant and lactating women or the women of child bearing age who are not practicing the effective means of contraception, Patients who will receive some other drug during the study besides that in the protocol that could alter the pharmacokinetic/ pharmacodynamic profile of the study drug, Patients with known alcohol or drug abuse, Any condition that, in the opinion of the investigator, does not justify the patient?s inclusion in the study

Outcomes

Primary Outcomes

Not specified

Similar Trials